Bausch Health Companies Inc (BHC)vsMerck & Company Inc (MRK)
BHC
Bausch Health Companies Inc
$5.37
+2.09%
HEALTHCARE · Cap: $1.89B
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 525% more annual revenue ($65.77B vs $10.53B). MRK leads profitability with a 13.6% profit margin vs -11.5%. BHC appears more attractively valued with a PEG of 0.01. BHC earns a higher WallStSmart Score of 69/100 (B-).
BHC
Strong Buy69
out of 100
Grade: B-
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BHC.
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 44 in profit
Earnings expanding 1368.0% YoY
Conservative balance sheet, low leverage
Strong operational efficiency at 20.6%
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Distress zone — elevated risk
Currently unprofitable
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BHC
The strongest argument for BHC centers on PEG Ratio, Return on Equity, EPS Growth. Revenue growth of 11.7% demonstrates continued momentum. PEG of 0.01 suggests the stock is reasonably priced for its growth.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : BHC
The primary concerns for BHC are Market Cap, Altman Z-Score, Profit Margin.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
BHC profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
BHC carries more volatility with a beta of 0.41 — expect wider price swings.
BHC is growing revenue faster at 11.7% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
BHC scores higher overall (69/100 vs 50/100) and 11.7% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bausch Health Companies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Bausch Health Companies Inc. develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology and dermatology. The company is headquartered in Laval, Canada.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?